A Randomized, Open-label Non-inferiority Study to Compare Safety and Efficacy of Labeled Versus Wait and Extend Regimen of Lucentis (Ranibizumab) in Turkish Patients With Visual Impairment Due to Diabetic Macular Edema.
Phase of Trial: Phase III
Latest Information Update: 25 Jun 2019
Price : $35 *
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms SALUTE-D
- Sponsors Novartis
- 31 Oct 2017 Status changed from recruiting to completed.
- 28 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
- 28 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.